The English text is an unofficial
translation. In case of any discrepancies between the Swedish text
and the English translation, the Swedish text shall
prevail.
Press release
Lund on October 18, 2018
Notice of Extraordinary General Meeting in
Enzymatica AB (publ)
The shareholders in Enzymatica AB
(publ), reg. no 556719-9244 (the "Company") are hereby invited to
attend the Extraordinary General Meeting ("EGM") to be held on
Monday November 5, 2018 at 09.30 a.m. at Elite Hotel Ideon,
Scheelevägen 27 in Lund. Registration for the EGM starts at 09.00
a.m.
Right to participate and
notice
Only shareholders that are recorded in their own name in the
Company's share ledger kept by Euroclear Sweden AB (The Swedish
Central Securities Depository Euroclear Sweden AB) as of
October 29, 2018 and also have given notice on October 29, 2018 to
the Company of their intent to participate, preferably no later
than 4.00 p.m., have the right to participate in the EGM. A
shareholder may be accompanied by not more than two advisors,
provided that the number of such advisors has been notified to the
Company no later than the aforementioned time. Proxies do not need
to notify the number of advisors in advance.
Notice may be given in writing to Enzymatica AB
(publ), att: EGM, Ideon Science Park, 223 70 Lund or by e-mail to
louise.forssell@enzymatica.com. The notice should specify the
shareholder's name, personal identity or company registration
number, address, work-hour telephone number and shareholding, and
names of any advisors.
Trustee-registered
shares
In order to be entitled to participate in the EGM, shareholders
whose shares are trustee-registered must temporarily register their
shares in their own names. Such registration should be requested
from the trustee, and must be executed with Euroclear Sweden AB on
October 29, 2018. Shareholders that wish to execute such
registration must, well in advance before the said date, notify its
trustee thereof.
Proxies
If a shareholder intends to participate by proxy, the proxy must
bring a written and dated proxy signed by the shareholder in
original to the meeting. The proxy may not be older than five
years. Proxy forms can be downloaded from the Company's website,
www.enzymatica.com. If the proxy is issued by a legal entity, the
proxy must also bring current registration certificate (Sw.
registreringsbevis) of the legal entity or
similar document of authorization for the legal entity.
Proposed agenda
-
Opening of the meeting
-
Election of chairman of the meeting
-
Preparation and approval of the register of
voters
-
Election of persons to confirm the minutes
-
Determination as to whether the meeting has been
duly convened
-
Approval of the agenda
-
Approval of the resolution by the Board of
Directors on a rights issue with preferential rights for the
Company's shareholders
-
Closing of the meeting
Resolution proposals
Election of chairman of the
meeting (item 2)
The Board of Directors has proposed that legal counsel Madeleine
Rydberger shall be elected chairman of the meeting.
Approval of the resolution by the
Board of Directors on a rights issue with preferential rights for
the Company's shareholders (item 7)
The Board of Directors of Enzymatica AB (publ) has
resolved, subject to approval by the Extraordinary General Meeting
on 5 November 2018, on a new share issue on the following terms and
conditions.
The company's share capital shall be increased by not more than SEK
2,077,436.20. A maximum number of 51,935,888 new shares shall be
issued. The subscription price shall be SEK 1.90 for each new
share. The shareholders of the company shall have preferential
right to subscribe for new shares in relation to the number of
shares previously held by them. For each existing share one (1)
subscription right is obtained. Seven (7) subscription rights
entitles to subscription for four (4) new shares. The record date
for entitlement to participate in the new share issue with
preferential right shall be 12 November 2018.
If not all the shares are subscribed for by
exercise of subscription rights, the Board of Directors shall
resolve on allotment of shares subscribed for without the exercise
of subscriptions rights up to the maximum amount of the share
issue. Such shares shall in firstly be allotted to those who have
also subscribed for shares by exercise of subscription rights,
regardless of them being shareholders on the record date or not,
pro rata in relation to the number of subscription rights which
each person has exercised for subscription. Secondly, such shares
shall be allotted to members of the management group who have
applied for subscription without the exercise of subscription
rights, and thirdly to others, pro rata in relation to their
applied interest. To the extent that allotment in accordance to the
above cannot be made pro rata, allotment shall be made by drawing
of lots. Any remaining shares shall be allotted to those who have
guaranteed the new share issue, pro rata in relation to the
guaranteed amount.
Subscription for new shares by exercise of
subscription rights shall be made by simultaneously cash payment
during the period as from 14 November up to and including 28
November 2018. Subscription for new shares without the exercise of
subscription rights shall take place during the same period on a
separate subscription list. Payment for new shares subscribed for
without the exercise of subscription rights shall be made in cash
no later than on the second bank day from dispatch of the contract
note setting forth the allotment of shares. The Board of Directors
shall be entitled to extend the period for subscription and
payment. The new shares shall entitle to dividend as from the first
record date for dividend to occur after the registration of the new
share issue with the Swedish Companies Registration
Office.
The Board of Directors, or whoever the Board of Directors may
appoint, shall be authorised to make such minor adjustments of the
above proposal as may prove necessary in connection with the
registration with the Swedish Companies Registration Office or
Euroclear Sweden AB. Documents pursuant to Chapter 13, Section 6 of
the Companies Act have been prepared.
Total number of shares and
votes
The total number of shares and votes in the Company amounts as per
the date of this notice to 90,887,808. The Company does not hold
any own shares.
The shareholders are reminded of their right to
request information from the Board of Directors and the CEO at the
meeting in accordance with Chap. 7 Sec. 32 of the Swedish Companies
Act (Sw. aktiebolagslagen (2005:551)).
Meeting documents
The Board of Directors' complete proposal for resolution pursuant
to item 7, Enzymatica's Articles of Association and documentation
pursuant to Chap. 13 Sec. 6 of the Swedish Companies Act are
available for the shareholders at the Company's website and at the
Company at its abovementioned address at the latest from October
22, 2018 and will free of charge be sent to the shareholders upon
their request to the Company, provided that such shareholders state
their current address.
Processing of personal
data
For information about the processing of your personal data, see the
section Extraordinary General Meeting 5 November
2018 on the Company's website, www.enzymatica.com .
Lund in October 2018
The Board of Directors of Enzymatica AB (publ)
For
further information, contact:
Fredrik Lindberg, CEO Enzymatica AB
Phone: 0708-86 53 70 | E-mail:
fredrik.lindberg@enzymatica.com
Enzymatica
Enzymatica AB is a Swedish life science company that develops and
sells medical devices for infection-related diseases. The products
are based on a barrier technology that includes marine enzymes. The
company's first product is ColdZyme® Mouth Spray, which can prevent
colds and reduce the duration of disease. The product has been
launched in about ten markets. The strategy is to continue to grow
by strengthening the Company's position in existing markets and
expanding into new geographic markets through established partners.
The company has its headquarter in Lund and is listed on Nasdaq
First North, Sweden. For more information,
visit: www.enzymatica.com.
Enzymaticas Certified Adviser is Erik Penser Bank.
Enzymatica - Notice EGM
2018-11-05
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From May 2024 to Jun 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2023 to Jun 2024